Enrollment completed for ph 2b of ARQ-154 in scalp psoriasis

Roflumilast foam is a once-daily topical foam formulation of a highly potent and selective phosphodiesterase type 4 inhibitor (PDE4 inhibitor) that the Company is developing particularly to treat inflammatory dermatoses in hair-bearing areas of the body such as the scalp.

“An estimated 8.6 million Americans are afflicted with chronic psoriasis, and nearly half of those people have scalp involvement, an area where topical treatment of scalp plaques is complicated by the difficulty of delivering topical drugs under the hair and to the surface of the skin,” said Frank Watanabe, Arcutis’ President and Chief Executive Officer. “We developed roflumilast foam as a convenient, once daily, easy-to-use foam that is safe for chronic use and appropriate for application in hair-bearing areas, such as the scalp, where a cream, lotion, or ointment is not suitable. We believe roflumilast foam may provide a new treatment option for physicians and patients, with the potential to show significant symptomatic improvement similar to high-potency steroids, while at the same time maintaining a low risk of toxicity or side effects.”